Wells Fargo analyst Benjamin Burnett initiated coverage of Avadel Pharmaceuticals (AVDL) with an Equal Weight rating and $16 price target The firm believes the shares already reflect much of Avadel ‘s recent commercial outperformance. However, Xyrem generics and the possible entrance of orexins add uncertainty to Lumryz’s long-term growth trajectory, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals price target raised to $20 from $13 at UBS
- Avadel Pharmaceuticals Reports Strong Earnings and Growth
- Avadel Pharmaceuticals price target raised to $18 from $16 at Deutsche Bank
- Avadel Pharmaceuticals price target raised to $24 from $22 at H.C. Wainwright
- Avadel Pharmaceuticals Reports Strong Q2 Growth